TNFSF10 and cancer: Drugs were first pre-screened individually (single agent treatment) for toxicity at a concentration of 20 μM using TRAIL-resistant PC3-TR prostate cancer cells; candidates that resulted in greater than 70% reduction in cancer cell viability were screened for TRAIL sensitization activity at a lower concentration of 10 μM.